FDA Approves Digital Pill
The agency approved Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication.
On Nov. 13, 2017, FDA announced it has approved Abilify MyCite (Otsuka Pharmaceutical Co., Ltd.), which is the first drug in the United States that has a digital ingestion tracking system. The pill has an embedded ingestible sensor that records when the medication is taken. Abilify MyCite treats schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and is also used as an add-on treatment for depression in adults.
The pill’s sensor sends a message to a wearable patch that transmits information to a mobile application, which allows patients, caregivers, and physicians to track the ingestion of the drug on a smartphone and through a web-based portal. The sensor and patch are made by Proteus Digital Health. Labeling information stresses that it has not been proven if tracking such information improves treatment regimens. Abilify MyCite also contains a boxed warning about the risks of antipsychotic drugs.
“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”
Source: FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
